Preliminary dermatopharmacokinetic study of flurbiprofen-containing tape (LC1702) in healthy adult males

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031230393

Enrollment

Registered

2023-10-12

Start date

2023-10-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy adult males

Interventions

Single and repeated transdermal administration of LC1702 and ADF.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: (1) Age: 20 to 40 years old (at the time of obtaining consent) (2) Persons whose BMI (Body Mass Index: weight (kg) / height (mm)2) is 18.5 kg/m2 or more and less than 25 kg/m2 (numbers are not rounded).

Exclusion criteria

Exclusion criteria: (1) Persons with hypersensitivity or idiosyncrasy to drugs, etc. (2) Persons with a history of bronchial asthma. (3) Persons with diseases of the gastrointestinal tract, heart, liver, kidneys, etc. that affect drug metabolism and excretion. (4) Persons with have skin wounds at the administration site, and those who have skin symptoms such as eczema, contact dermatitis, psoriasis, seborrheic dermatitis, dyschromatosis, and excessive sunburn at the administration site.

Design outcomes

Primary

Measure	Time frame
Calculation of drug amount in the stratum corneum	—

Contacts

Public ContactNoriko Kurihara

Tokyo Research Center of Clinical Pharmacology Co., Ltd.

n-kurihara@trcp.co.jp+81-3-5366-3006

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026